PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TECHNOLOGY • Segmentation by technology • Comparison by technology • Conventional testing – Market size and forecast 2017-2022 • Non-conventional testing – Market size and forecast 2017-2022 • Market opportunity by technology PART 08: CUSTOMER LANDSCAPE PART 09: SEGMENTATION BY END-USER • Segmentation by end-user • Comparison by end-user • Hospitals – Market size and forecast 2017-2022 • Diagnostic laboratories – Market size and forecast 2017-2022 • Academic and research institutes – Market size and forecast 2017-2022 • Market opportunity by end-user PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Adoption of NGS in cancer diagnostics • Preference for liquid biopsy over traditional biopsy • Increase in investment in cancer research PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Agilent Technologies • Becton, Dickinson and Company • Danaher • F. Hoffmann-La Roche • Illumina • Thermo Fisher Scientific PART 15: APPENDIX • List of abbreviations Exhibit 01: Related market Exhibit 02: Market characteristics Exhibit 03: Market segments Exhibit 04: Market definition - Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Solid tumor testing market in the US- Market size and forecast 2017-2022 ($ bn) Exhibit 08: Solid tumor testing market in the US - Year-over-year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 and 2022 Exhibit 17: Solid tumor testing market in the US by technology – Market share 2017-2022 (%) Exhibit 18: Comparison by technology Exhibit 19: Conventional tests for solid tumors associated with various types of cancer Exhibit 20: Conventional testing – Market size and forecast 2017-2022 ($ bn) Exhibit 21: Conventional testing – Year over year growth 2018-2022 (%) Exhibit 22: Non-conventional testing – Market size and forecast 2017-2022 ($ bn) Exhibit 23: Non-conventional testing – Year over year growth 2018-2022 (%) Exhibit 24: Market opportunity by technology Exhibit 25: Customer landscape Exhibit 26: Solid tumor testing market in the US by end-user – Market share 2017-2022 (%) Exhibit 27: Comparison by end-user Exhibit 28: Hospitals – Market size and forecast 2017-2022 ($ bn) Exhibit 29: Hospitals – Year over year growth 2018-2022 (%) Exhibit 30: Diagnostic laboratories – Market size and forecast 2017-2022 ($ bn) Exhibit 31: Diagnostic laboratories – Year over year growth 2018-2022 (%) Exhibit 32: R&D funding for cancer 2013-2016 ($ millions) Exhibit 33: Academic and research institutes– Market size and forecast 2017-2022 ($ bn) Exhibit 34: Academic and research institutes – Year over year growth 2018-2022 (%) Exhibit 35: Market opportunity by end-user Exhibit 36: Cost of sequencing per genome 2001-2015 ($) Exhibit 37: Vendor landscape Exhibit 38: Landscape disruption Exhibit 39: Vendors covered Exhibit 40: Vendor classification Exhibit 41: Market positioning of vendors Exhibit 42: Agilent Technologies overview Exhibit 43: Agilent Technologies– Business segments Exhibit 44: Agilent Technologies – Organizational developments Exhibit 45: Agilent Technologies – Geographic focus Exhibit 46: Agilent Technologies – Segment focus Exhibit 47: Agilent Technologies – Key offerings Exhibit 48: Becton, Dickinson and Company overview Exhibit 49: Becton, Dickinson and Company – Business segments Exhibit 50: Becton, Dickinson and Company – Organizational developments Exhibit 51: Becton, Dickinson and Company – Geographic focus Exhibit 52: Becton, Dickinson and Company – Segment focus Exhibit 53: Becton, Dickinson and Company – Key offerings Exhibit 54: Danaher overview Exhibit 55: Danaher – Business segments Exhibit 56: Danaher – Organizational developments Exhibit 57: Danaher– Geographic focus Exhibit 58: Danaher– Segment focus Exhibit 59: Danaher – Key offerings Exhibit 60: F. Hoffmann-La Roche overview Exhibit 61: F. Hoffmann-La Roche– Business segments Exhibit 62: F. Hoffmann-La Roche – Organizational developments Exhibit 63: F. Hoffmann-La Roche– Geographic focus Exhibit 64: F. Hoffmann-La Roche– Segment focus Exhibit 65: F. Hoffmann-La Roche – Key offerings Exhibit 66: Illumina overview Exhibit 67: Illumina – Business segments Exhibit 68: Illumina – Organizational developments Exhibit 69: Illumina – Geographic focus Exhibit 70: Illumina – Segment focus Exhibit 71: Illumina – Key offerings Exhibit 72: Thermo Fisher Scientific overview Exhibit 73: Thermo Fisher Scientific– Business segments Exhibit 74: Thermo Fisher Scientific– Organizational developments Exhibit 75: Thermo Fisher Scientific– Geographic focus Exhibit 76: Thermo Fisher Scientific– Segment focus Exhibit 77: Thermo Fisher Scientific– Key offerings

Agilent Technologies Becton, Dickinson and Company Danaher F. Hoffmann-La Roche Illumina Thermo Fisher Scientific